Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Research

General Research | Delavirdine (Rescriptor) | Efavirenz (Sustiva, Stocrin) | Nevirapine (Viramune)

See also: Medication Side Effects | Drug Interactions

Show Archived (Historical) Articles

General Research

Non-Nucleoside Reverse Transcriptase Inhibitors in Development (February 6, 2009)
To read PDF, click here
From AIDS InfoNet
When HIV Regimens Fail, Resistance Risk Appears Higher on NNRTIs Than Protease Inhibitors (October 3, 2008)
From aidsmap.com
Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From The Body PRO
NNRTIs: The Next Generation Approaches (Part II) (December 14, 2006)
From The Body PRO
People With History of Depression More Likely to Stop Efavirenz Due to Mental Health Problems (July 26, 2006)
From aidsmap.com
HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO
HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO

Efavirenz (Sustiva, Stocrin)

Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (November/December 2008)
In HIV Treatment Bulletin, from HIV i-Base
Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here
In Project Inform Perspective, from Project Inform
Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
In aidsmap.com
Sustiva Study Finds Ethnicity, Quality of Life Predict Treatment Outcomes (April 1, 2008)
From Project Inform
High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSMeds.com
Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Baseline NNRTI Resistance and Virologic Failure in Treatment-Naive Patients on Efavirenz: An Interview With Daniel Kuritzkes, M.D. (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Efavirenz-Based Regimens Best Lopinavir/Ritonavir Regimens in Head-to-Head Trial (August 17, 2006)
In XVI International AIDS Conference
ACTG 384 Substudy: DEXA Outcomes in Antiretroviral-Naive Patients Randomized to Efavirenz or Nelfinavir or Both Plus Nucleoside Backbone (August 16, 2006)
In XVI International AIDS Conference
Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
HIV JournalView: Efavirenz Has No Significant, Lasting Impact on Neuropsychological Performance (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

Nevirapine (Viramune)

Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here
In Project Inform Perspective, from Project Inform
High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSMeds.com
Nevirapine-Associated Toxicity Less Frequent in Non-Naive Patients (August 17, 2006)
In XVI International AIDS Conference
Hepatotoxicity in IDUs and Non-IDUs Receiving Nevirapine-Based HAART (August 16, 2006)
In XVI International AIDS Conference
Nevirapine Resistance May Persist in Some Pregnant Women, Study Finds (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
In Uganda, Three-NRTI Regimen Including Abacavir Is Better Tolerated Than Nevirapine-Based Regimen (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections